| Cancer regression in patients after transfer of genetically engineered lymphocytes RA Morgan, ME Dudley, JR Wunderlich, MS Hughes, JC Yang, ... Science 314 (5796), 126-129, 2006 | 4239 | 2006 |
| T-cell transfer therapy targeting mutant KRAS in cancer E Tran, PF Robbins, YC Lu, TD Prickett, JJ Gartner, L Jia, A Pasetto, ... New England Journal of Medicine 375 (23), 2255-2262, 2016 | 1399 | 2016 |
| Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy RA Morgan, N Chinnasamy, D Abate-Daga, A Gros, PF Robbins, Z Zheng, ... Journal of immunotherapy 36 (2), 133-151, 2013 | 1383 | 2013 |
| Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer N Zacharakis, H Chinnasamy, M Black, H Xu, YC Lu, Z Zheng, A Pasetto, ... Nature medicine 24 (6), 724-730, 2018 | 855 | 2018 |
| Immunogenicity of somatic mutations in human gastrointestinal cancers E Tran, M Ahmadzadeh, YC Lu, A Gros, S Turcotte, PF Robbins, ... Science 350 (6266), 1387-1390, 2015 | 805 | 2015 |
| Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability CJ Cohen, Y Zhao, Z Zheng, SA Rosenberg, RA Morgan Cancer research 66 (17), 8878-8886, 2006 | 617 | 2006 |
| Transformation by Wnt family proteins correlates with regulation of beta-catenin. H Shimizu, MA Julius, M Giarre, Z Zheng, AM Brown, J Kitajewski Cell growth & differentiation: the molecular biology journal of the American …, 1997 | 562 | 1997 |
| Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions PF Robbins, YF Li, M El-Gamil, Y Zhao, JA Wargo, Z Zheng, H Xu, ... The Journal of Immunology 180 (9), 6116-6131, 2008 | 445 | 2008 |
| Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma L Zhang, RA Morgan, JD Beane, Z Zheng, ME Dudley, SH Kassim, ... Clinical cancer research 21 (10), 2278-2288, 2015 | 430 | 2015 |
| A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity Y Zhao, QJ Wang, S Yang, JN Kochenderfer, Z Zheng, X Zhong, ... The Journal of Immunology 183 (9), 5563-5574, 2009 | 426 | 2009 |
| High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation Y Zhao, Z Zheng, CJ Cohen, L Gattinoni, DC Palmer, NP Restifo, ... Molecular therapy 13 (1), 151-159, 2006 | 370 | 2006 |
| Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma RA Morgan, LA Johnson, JL Davis, Z Zheng, KD Woolard, EA Reap, ... Human gene therapy 23 (10), 1043-1053, 2012 | 360 | 2012 |
| Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment L Zhang, SP Kerkar, Z Yu, Z Zheng, S Yang, NP Restifo, SA Rosenberg, ... Molecular therapy 19 (4), 751-759, 2011 | 349 | 2011 |
| Pilot trial of adoptive transfer of chimeric antigen receptor–transduced T cells targeting EGFRvIII in patients with glioblastoma SL Goff, RA Morgan, JC Yang, RM Sherry, PF Robbins, NP Restifo, ... Journal of immunotherapy 42 (4), 126-135, 2019 | 332 | 2019 |
| High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of … RA Morgan, ME Dudley, YYL Yu, Z Zheng, PF Robbins, MR Theoret, ... The Journal of Immunology 171 (6), 3287-3295, 2003 | 309 | 2003 |
| Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions MS Hughes, YYL Yu, ME Dudley, Z Zheng, PF Robbins, Y Li, ... Human gene therapy 16 (4), 457-472, 2005 | 308 | 2005 |
| Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers FJ Lowery, S Krishna, R Yossef, NB Parikh, PD Chatani, N Zacharakis, ... Science 375 (6583), 877-884, 2022 | 292 | 2022 |
| Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen MAGE-A3 YC Lu, LL Parker, T Lu, Z Zheng, MA Toomey, DE White, X Yao, YF Li, ... Journal of Clinical Oncology 35 (29), 3322-3329, 2017 | 289 | 2017 |
| High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines Y Zhao, AD Bennett, Z Zheng, QJ Wang, PF Robbins, LYL Yu, Y Li, ... The Journal of Immunology 179 (9), 5845-5854, 2007 | 272 | 2007 |
| Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines Y Zhao, Z Zheng, PF Robbins, HT Khong, SA Rosenberg, RA Morgan The Journal of Immunology 174 (7), 4415-4423, 2005 | 272 | 2005 |
